A vitamin D analogue, eldecalcitol, enhances expression of fast myosin heavy chain subtypes in differentiated C2C12 myoblasts.

[1]  E. Itoi,et al.  1α,25‐dihydroxyvitamin D3 enhances fast‐myosin heavy chain expression in differentiated C2C12 myoblasts , 2012, Cell biology international.

[2]  P. L. McCormack,et al.  Erratum to: Eldecalcitol: a review of its use in the treatment of osteoporosis , 2011, Drugs.

[3]  T. Sone,et al.  A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study. , 2011, Bone.

[4]  Keith C. Norris,et al.  1,25(OH)2vitamin D3 stimulates myogenic differentiation by inhibiting cell proliferation and modulating the expression of promyogenic growth factors and myostatin in C2C12 skeletal muscle cells. , 2011, Endocrinology.

[5]  Y. Tanigawara,et al.  Overview of the clinical pharmacokinetics of eldecalcitol, a new active vitamin D3 derivative , 2011 .

[6]  Toshitaka Nakamura,et al.  Pharmacokinetics of eldecalcitol in primary osteoporosis patients - Randomized, double-blind, multicentre, long-term phase III clinical study , 2011 .

[7]  K. Miyata.  Effects of Eldecalcitol on the Pharmacokineticsof the CYP3A4 Substrate, Simvastatin―Double Blind, Randomized, Placebo－Controlled,Parallel Group Comparative Studyin Healthy Male Volunteers― , 2011 .

[8]  J B Wong,et al.  Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials , 2009, BMJ : British Medical Journal.

[9]  F. Booth,et al.  IGF-I activates the mouse type IIb myosin heavy chain gene. , 2009, American journal of physiology. Cell physiology.

[10]  Michael A. Kiraly,et al.  Vitamin D as a Neuroactive Substance: Review , 2006, TheScientificWorldJournal.

[11]  J. Kelsey,et al.  Reducing the risk for distal forearm fracture: preserve bone mass, slow down, and don’t fall! , 2005, Osteoporosis International.

[12]  D. Pette,et al.  Myosin heavy chain isoforms in histochemically defined fiber types of rat muscle , 2004, Histochemistry.

[13]  G. Guyatt,et al.  VIII: Meta-Analysis of the Efficacy of Vitamin D Treatment in Preventing Osteoporosis in Postmenopausal Women , 2002 .

[14]  Y. Iwabuchi,et al.  Synthesis and biological characterization of 1α,24,25-trihydroxy-2β-(3-hydroxypropoxy)vitamin D3 (24-hydroxylated ED-71) , 2001, Steroids.

[15]  T. Okano,et al.  History of the development of new vitamin D analogs: studies on 22-oxacalcitriol (OCT) and 2β-(3-hydroxypropoxy)calcitriol (ED-71) , 2001, Steroids.

[16]  M. Haussler,et al.  The Nuclear Vitamin D Receptor: Biological and Molecular Regulatory Properties Revealed , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  K. Kumaki,et al.  DIFFERENTIAL TIME COURSE OF INDUCTION OF 1α,25-DIHYDROXYVITAMIN D3-24-HYDROXYLASE mRNA EXPRESSION IN RATS BY 1α,25-DIHYDROXYVITAMIN D3 AND ITS ANALOGS , 1997 .

[18]  C. Reggiani,et al.  Myosin isoforms in mammalian skeletal muscle. , 1994, Journal of applied physiology.

[19]  N. Tsugawa,et al.  Regulatory activities of 2β-(3-hydroxypropoxy)-1α,25-dihydroxyvitamin D3, a novel synthetic vitamin D3 derivative, on calcium metabolism , 1989 .

[20]  R. Kumar,et al.  The metabolism and mechanism of action of 1,25-dihydroxyvitamin D3. , 1986, Kidney international.

[21]  H. Blau,et al.  1,25-dihydroxyvitamin D3 receptors and hormonal responses in cloned human skeletal muscle cells. , 1986, Endocrinology.

[22]  C. Heizmann,et al.  Analysis of myosin light and heavy chain types in single human skeletal muscle fibers. , 1981, European journal of biochemistry.

[23]  J. Eastwood,et al.  The effect of 25-hydroxy vitamin D3 in the osteomalacia of chronic renal failure. , 1977, Clinical science and molecular medicine.